Erratum: Stabilization of vaccines and antibiotics in silk and eliminating the cold chain (Proceedings of the National Academy of Sciences of the United States of America (2012) 109 (11981-11986) 10.1073/pnas.1206210109);Stabilization of vaccines and antibiotics in silk and eliminating the cold chain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 30, 2012, Pages 11981-11986

  Zhang, Jeney ^a   Pritchard, Eleanor ^a   Hu, Xiao ^a   Valentin, Thomas ^a   Panilaitis, Bruce ^a   Omenetto, Fiorenzo G ^a   Kaplan, David L ^a  

^a Tufts University   (United States)

Author keywords

Measles; Mumps; Penicillin; Rubella

Indexed keywords

ANTIBIOTIC AGENT; BIOMATERIAL; MEASLES MUMPS RUBELLA VACCINE; SILK FIBROIN; TETRACYCLINE; VACCINE;

ARTICLE; DRUG DEGRADATION; DRUG STABILITY; DRUG STORAGE; FILM; FREEZE DRYING; NONHUMAN; PRIORITY JOURNAL; SHELF LIFE; SHIPPING; STORAGE TEMPERATURE; STORAGE TIME; THERMOSTABILITY; TIME;

RUBELLA;

EID: 84864364745     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608261113     Document Type: Erratum

References (47)

1. Chen X, et al. (2011) Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Controlled Release 152:349-355.
2. Yager P, et al. (2006) Microfluidic diagnostic technologies for global public health. Nature 442:412-418. (Pubitemid 44264785)
3. Cheyne J (1989) Vaccine delivery management. Rev Infect Dis 11:S617-S622.
4. Wolfson LJ, et al. (2008) Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull W H O 86:27-39.
5. Das P (2004) Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis 4(12):719.
6. Bishai DM (1992) Vaccine storage practices in pediatric offices. Pediatrics 89:193-196.
7. Cheriyan E (1993) Monitoring the vaccine cold chain. Arch Dis Child 69:600-601.
8. Adu FD, Adedeji AA, Esan JS, Odusanya OG (1996) Live viral vaccine potency: an index for assessing the cold chain system. Public Health 110:325-330. (Pubitemid 26401785)
9. Arya SC (2001) Stabilization of vaccines: To be or not to be. Vaccine 19:595-597.
10. UNAIDA, UNICEF, UNESCO, UNFPA, WB, WHODavey S, ed. (2000) A key to prosperity: Success stories in developing countries. Health (World Health Organization, Communicable Diseases, Geneva).
11. Leal-Egaña A, Scheibel T (2010) Silk-based materials for biomedical applications. Biotechnol Appl Biochem 55:155-167.
12. Meinel L, et al. (2005) The inflammatory responses of silk films in vitro and in vivo. Biomaterials 26:147-155. (Pubitemid 38789097)
13. Seo Y, et al. (2009) Increase in cell migration and angiogenesis in a composite silk scaffold for tissue-engineered ligaments. J Orthop Res 27:495-503.
14. Panilaitis B, et al. (2003) Macrophage responses to silk. Biomaterials 24:3079-3085. (Pubitemid 36944938)
15. Altman GH, et al. (2003) Silk-based biomaterials. Biomaterials 24:401-416. (Pubitemid 35291198)
16. Wang X, et al. (2008) Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. Biomaterials 29:894-903. (Pubitemid 350278534)
17. Omenetto F, Kaplan DL (2010) From silk cocoon to medical miracle. Sci Am303(5):76-77.
18. Vepari C, Kaplan DL (2007) Silk as a biomaterial. Prog Polym Sci 32(8-9):991-1007. (Pubitemid 47198292)
19. Lawrence BD, Cronin-Golomb M, Georgakoudi I, Kaplan DL, Omenetto FG (2008) Bioactive Silk Protein Biomaterial Systems for Optical Devices. Biomacromolecules 9:1214-1220. (Pubitemid 351639575)
20. Guziewicz N, Best A, Perez-Ramirez B, Kaplan DL (2011) Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies. Biomaterials 32:2642-2650.
21. Pritchard EM, Kaplan DL (2011) Silk fibroin biomaterials for controlled release drug delivery. Expert Opin Drug Delivery 8:797-811.
22. Lu Q, et al. (2010) Stabilization and release of enzymes from silk films. Macromol Biosci 10:359-368.
23. Colinet G, Rossignol J, Peetermans J (1982) A study of the stability of a bivalent measles-mumps vaccine. J Biol Stand 10:341-346. (Pubitemid 13186423)
24. McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR (1980) Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. J Biol Stand 8:281-287. (Pubitemid 11220839)
25. Galazka A, Milstien J, ZaffranM(1998) Thermostability of Vaccines. Global Programme for Vaccines and Immunization (World Health Organization, Geneva).
26. Fleming A (1929) On the antibacterial action of cultures of a penicillium with special reference to their use in the isolation of B. influenza. Br J Exp Pathol 3:226-236.
27. Benedict RG, Schmidt WH, Coghill RD, Oleson PA (1945) The stability of penicillin in aqueous solution. J Bacteriol 49:85-95.
28. Xuan R, Arisi L, Wang Q, Yates SR, Biswas KC (2010) Hydrolysis and photolysis of oxytetracycline in aqueous solution. J Environ Sci Health part B 45:73-78.
29. Sun Y, Scruggs DW, Peng Y, Johnson JR, Shukla AJ (2004) Issues and challenges in developing long-acting veterinary antibiotic formulations. Adv Drug Delivery Rev 56:1481-1496. (Pubitemid 38748828)
30. Tsioris K, et al. (2012) Fabrication of silk microneedles for controlled-release drug delivery. Adv Funct Mater 22:330-335.
31. Packer L, Colowick SP, Kaplan NO (2002) Methods in enzymology, ed L Packer (Academic Press, California, USA), Volume 349.
32. Hall WW, Martin SJ (1973) Purification and Characterization of Measles Virus. J Gen Virol 19:175-188.
33. Merz DC,Wolinsky JS (1983) Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology 131:328-340. (Pubitemid 14175436)
34. Gianfreda L, Modafferi M, Greco G, Jr (1984) Enzyme stabilization towards thermal, chemical and proteolytic deactivation. Enzyme Microb Technol 7:78-82.
35. Jin HJ, Kaplan DL (2003) Mechanism of silk processing in insects and spiders. Nature 424:1057-1061.
36. Chen D, Kristensen D (2009) Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines 8:547-558.
37. Ausar SF, Hudson TR, Hudson MH, Vedvick TS, Middaugh CR (2006) Conformational stability and disassembly of Norwalk virus like particles: effect of pH and temperature. J Biol Chem 281:19478-19488. (Pubitemid 44035452)
38. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR (2003) Minireview: Thermal stability of vaccines. J Pharm Sci 92(2):218-231.
39. Li S, Schoneich C, Borchardt RT (1994) Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies of stabilization. Biotechnol Bioeng 48:490-500.
40. Waterman K, Adami RC (2005) Accelerated aging: Prediction of chemical stability of pharmaceuticals. Int J Pharm 293:101-125. (Pubitemid 40381085)
41. Hu X, Kaplan DL, Cebe P (2007) Effect of water on the thermal properties of silk fibroin. Thermochim Acta 461:137-144. (Pubitemid 47187461)
42. Pritchard EM, Dennis PB, Omenetto F, Naik RR, Kaplan DL (2012) Physical and chemical aspects of stabilization of compounds in silk. Biopolymers 97:479-498.
43. Wang Y, Kim H-J, Vunjak-Novakovic G, Kaplan DL (2006) Stem cell-based tissue engineering with silk biomaterials. Biomaterials 2:6064-6082. (Pubitemid 44437574)
44. Pritchard EM, Szybala C, Boison D, Kaplan DL (2010) Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J Controlled Release 144:159-167.
45. Boyle VJ, Fancher ME, Ross RW (1973) Rapid, modified Kirby-Bauer susceptibility test with single, high-concentration antimicrobial disks. Antimicrob Agents Chemother 3:418-424.
46. Hu ZQ, Zhao W-H, Hara Y, Shimamura T (2001) Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 28:361-364. (Pubitemid 32898806)
47. Worrall EE, Litamoi JK, Seck BM, Ayelet G (2001) Xerovac: an ultra rapid method for the dehydration and preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines. Vaccine 19:834-839.